Abstract:Cell cycle dysregulation, characterised by aberrant activation of cyclin dependent kinases (CDKs), is a hallmark of cancer. After years of research on the first and second generations of less selective CDK inhibitors with unfavourable clinical activity and toxicity profiles, CDK4/6 inhibitors become the first and only class of highly specific CDK inhibitors being approved for cancer treatment to date. CDK4/6 inhibitors have transformed the treatment paradigm of estrogen receptor-positive (ER +) breast cancer, dramatically improving the survival outcomes of these patients when incorporated with conventional endocrine therapies in both the first and later-line settings. Currently, the efficacies of CDK4/6 inhibitors in other breast cancer subtypes and cancers are being actively explored. All three CDK4/6 inhibitors have demonstrated very similar clinical efficacies. However, being the least similar structurally, abemaciclib is the only CDK4/6 inhibitor with single agent activity in refractory metastatic ER + breast cancer, the ability to cross the blood brain barrier efficiently, and a distinct toxicity profile of lower myelosuppression such that it can be dosed continuously. Here, we further discuss the distinguishing features of abemaciclib as compared to the other two CDK4/6 inhibitors, palbociclib and ribociclib. Besides being the most potent inhibitor of CDK4/6, abemaciclib exhibits a wider selectivity towards other CDKs and kinases, and functions through additional mechanisms of action besides inducing G1 cell cycle arrest, in a dose dependent manner. Hence, abemaciclib has the potential to act independently of the CDK4/6-cyclin D-RB pathway, resulting in crucial implications on the possibly expanded clinical indications and predictive biomarkers of abemaciclib, in contrast to the other CDK4/6 inhibitors. The current status of preclinical evidence and clinical studies of abemaciclib as a single agent and in combination treatment in breast and other cancers, together with its potential predictive biomarkers, is also summarised in this review.

Cyclin-Dependent Kinase 4 and 6 Inhibitors: A Quantum Leap in the Treatment of Advanced Breast Cancers

Cyclin-dependent Kinase Inhibition and Its Intersection with Immunotherapy in Breast Cancer: More Than CDK4/6 Inhibition

Application of CDK4 / 6 Inhibitors in the Treatment of Hormone Receptor-Positive Breast Cancer

Cyclin-Dependent Kinases 4/6 Inhibitors in Breast Cancer: Current Status, Resistance, and Combination Strategies

Cyclin-dependent kinase 4/6 inhibitors in the treatment of advanced or metastatic breast cancer

The Use of Cyclin-Dependent Tyrosine Kinase 4/6 (CDK4/6) Inhibitors in Breast Cancer

Cyclin-dependent Kinase 4 and 6 Inhibitors at the Crossroads: the Combinational Therapeutic Strategies in Breast Cancer—a Narrative Review

&Lt;p>current Therapeutic Progress of CDK4/6 Inhibitors in Breast Cancer</p>

Role of cyclin-dependent kinase 4/6 inhibitors in the current and future eras of cancer treatment

Progress of CDK4/6 Inhibitor Palbociclib in the Treatment of Cancer.

The Roles of Cyclin-Dependent Kinases in Cell-Cycle Progression and Therapeutic Strategies in Human Breast Cancer

Recent progress of CDK4/6 inhibitors' current practice in breast cancer

A Narrative Review about CDK4/6 Inhibitors in the Setting of Drug Resistance: Updates on Biomarkers and Therapeutic Strategies in Breast Cancer

Pharmacodynamic characteristics, safety profile, and interactions of CDK4/6 inhibitors (CDK4/6i) in HR+/HER2– advanced/metastatic breast cancer

Cyclin-dependent kinase 4/6 inhibitors as neoadjuvant therapy of hormone receptor-positive/HER2-negative early breast cancer: What do we know so far?

A unique CDK4/6 inhibitor: Current and future therapeutic strategies of abemaciclib

Targeting CDK4 and CDK6 in hormone-dependent cancers

Clinical considerations of CDK4/6 inhibitors in HER2 positive breast cancer

CDK4/6 inhibitors in the treatment of metastatic breast cancer: Focus on toxicity and safety

Targeting Cell Cycle in Breast Cancer: CDK4/6 Inhibitors

Mechanisms of sensitivity and resistance to CDK4/CDK6 inhibitors in hormone receptor-positive breast cancer treatment